查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2017493

IgA腎臟病：市場展望、流行病學、競爭格局、市場預測報告（2025-2035年）

IgA Nephropathy - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 154 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

市場概覽

  • 德國市場預計將從 1.16 億美元成長到 9.5 億美元（複合年成長率超過 20%）。
  • 推動這一成長的動力在於出現了新的標靶治療，這些療法超越了對症治療，解決了疾病的根本機制。

IgA腎臟病變概述

IgA腎臟病（IgAN）是全球最常見的原發性腎絲球腎炎，其特徵是免疫複合物沉積於腎臟，導致進行性腎損傷。此病由IgA1鉸鏈區O-連接糖鏈的異常糖基化引起，導致循環血液中缺乏半乳糖的IgA1（Gd-IgA1）水平升高。這些異常的IgA1分子可被糖鏈特異性IgA和IgG自體抗體識別，形成免疫複合物並沉積於腎小球，引起發炎。

IgA是黏膜免疫中的主要抗體，主要以IgA1和IgA2的形式存在，而黏膜相關淋巴組織產生的分泌型IgA則以多聚體的形式存在。在IgA腎病變中，這種免疫調節異常會導致持續性腎功能損害。

臨床上，IgA腎病進行性緩慢，約30-40%的患者會在20-30年內發展為末期腎功能衰竭（ESRD）。此病可表現為散發病例（90-95%）或遺傳性（5-10%），遺傳性病例往往預後嚴重，且進展為腎衰竭的速度較快。

主要亮點

  • IgAN 是一種慢性進行性腎臟疾病，具有進行性腎病 (ESRD) 的顯著長期風險。
  • 預計法國腎臟切片檢查病例數將從 1500 例逐漸增加到 1570 例（年複合成長率 0.4%）。

格式化和更新訊息

  • 詳細報告（PDF）
  • 市場預測模型（基於微軟Excel）
  • 流行病學數據（MS Excel，互動式工具）
  • 高階主管洞察（PPT簡報）
  • 其他功能：定期更新、自訂和顧問支援。
  • 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

  • 我們如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
  • 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
  • 未來十年市場收入和病患佔有率的預測是多少？
  • 哪些因素對市場趨勢影響最大？
  • 受訪專家對目前和新興療法有何看法？
  • 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
  • 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
  • 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

  • G8
    • 美國
    • EU5
      • 法國
      • 德國
      • 義大利
      • 西班牙
      • 英國
    • 日本
    • 中國

大公司

  • Keymed Biosciences Co.Ltd
  • Novartis Pharmaceuticals
  • Biohaven Therapeutics Ltd.
  • Jiangsu HengRui Medicine Co., Ltd.
  • RemeGen Co., Ltd.
  • Chengdu Suncadia Medicine Co., Ltd.
  • Guangdong Hengrui Pharmaceutical Co., Ltd
  • Beijing Mabworks Biotech Co., Ltd.
  • Calliditas Therapeutics AB
  • Rigerna Therapeutics Co., Ltd.;Rigerna Therapeutics（Beijing）Co., Ltd.
  • Biocity Biopharmaceutics Co., Ltd.
  • HI-Bio, A Biogen Company
  • Purespring Therapeutics Limited
  • Vera Therapeutics, Inc.
  • Visterra, Inc.
  • Otsuka Pharmaceutical Development &Commercialization, Inc.
  • Alpine Immune Sciences Inc, A Subsidiary of Vertex
  • Biogen
  • Sinocelltech Ltd.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Travere Therapeutics, Inc.
  • Arrowhead Pharmaceuticals
  • Haisco Pharmaceutical Group Co., Ltd.
  • Suzhou Sanegene Bio Inc.
  • ADARx Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen

目錄

第1章：主要調查結果及分析師說明

  • 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

  • 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

  • 重點
  • 發病率/盛行率
  • 已確診並接受藥物治療的患者人數
  • 合併症
  • 其他相關患者群

第4章 市場規模及預測

  • 重點
  • 市場促進因素與限制因素
  • 按藥物類別分類的趨勢
  • 各國具體趨勢

第5章 競爭情勢

  • 目前療法
    • 重點
    • 診斷和治療過程/演算法
    • 主要當前療法 - 概述和關鍵意見領袖概述
  • 新興療法
    • 重點
    • 值得關注的後期新療法—概述、市場上市預期和關鍵意見領袖概述。
    • 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

  • 主要未滿足的需求以及透過新興療法實現的未來可能性
  • TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

簡介目錄

IgA Nephropathy Market Outlook

Thelansis's "IgA Nephropathy Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential IgA Nephropathy treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

IgA Nephropathy Overview

IgA nephropathy (IgAN) is the most prevalent form of primary glomerulonephritis worldwide and is characterized by immune complex deposition in the kidneys, leading to progressive renal damage. The disease is driven by abnormal glycosylation of O-linked glycans in the hinge region of IgA1, resulting in elevated levels of galactose-deficient IgA1 (Gd-IgA1) in circulation. These abnormal IgA1 molecules are recognized by glycan-specific IgA and IgG autoantibodies, forming immune complexes that deposit in the glomeruli and trigger inflammation.

IgA, a key antibody in mucosal immunity, exists primarily as IgA1 and IgA2, with secretory IgA produced by mucosal-associated lymphoid tissues in polymeric form. In IgAN, this immune dysregulation leads to sustained kidney injury.

Clinically, IgAN follows a slow but progressive course, with approximately 30-40% of patients progressing to end-stage renal disease (ESRD) within 20-30 years. The disease may occur as sporadic (90-95%) or familial (5-10%) forms, with familial cases often associated with a more severe prognosis and faster progression to renal failure.

Key Highlights

  • IgAN is a chronic, progressive renal disease with significant long-term ESRD risk
  • France kidney biopsy cases expected to grow modestly from 1.5K to 1.57K (0.4% CAGR)

Market Overview

  • Germany market projected to grow from $116M to $950M (>20% CAGR)
  • Growth driven by emerging targeted therapies addressing underlying disease mechanisms, beyond supportive care

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

  • Keymed Biosciences Co.Ltd
  • Novartis Pharmaceuticals
  • Biohaven Therapeutics Ltd.
  • Jiangsu HengRui Medicine Co., Ltd.
  • RemeGen Co., Ltd.
  • Chengdu Suncadia Medicine Co., Ltd.
  • Guangdong Hengrui Pharmaceutical Co., Ltd
  • Beijing Mabworks Biotech Co., Ltd.
  • Calliditas Therapeutics AB
  • Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
  • Biocity Biopharmaceutics Co., Ltd.
  • HI-Bio, A Biogen Company
  • Purespring Therapeutics Limited
  • Vera Therapeutics, Inc.
  • Visterra, Inc.
  • Otsuka Pharmaceutical Development & Commercialization, Inc.
  • Alpine Immune Sciences Inc, A Subsidiary of Vertex
  • Biogen
  • Sinocelltech Ltd.
  • Jiangsu Hansoh Pharmaceutical Co., Ltd.
  • Travere Therapeutics, Inc.
  • Arrowhead Pharmaceuticals
  • Haisco Pharmaceutical Group Co., Ltd.
  • Suzhou Sanegene Bio Inc.
  • ADARx Pharmaceuticals, Inc.
  • Apellis Pharmaceuticals, Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amgen

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
    • Key takeaways
    • Dx and Tx journey/algorithm
    • Key current therapies - profiles and KOL insights
  • Emerging therapies
    • Key takeaways
    • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
    • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)